Cargando…
Pterostilbene enhances sorafenib’s anticancer effects on gastric adenocarcinoma
Sorafenib has been approved for the treatment of certain cancers in clinic. However, the effects of sorafenib on gastric adenocarcinoma (GAC) were still limited. This study aimed to evaluate both in vitro and in vivo efficacy of sorafenib in combination with pterostilbene (PTE) on the treatment of G...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686996/ https://www.ncbi.nlm.nih.gov/pubmed/33047871 http://dx.doi.org/10.1111/jcmm.15795 |
_version_ | 1783613440393216000 |
---|---|
author | Zhao, Tingting Wang, Chun Huo, Xinying He, Ming‐Liang Chen, Jinfei |
author_facet | Zhao, Tingting Wang, Chun Huo, Xinying He, Ming‐Liang Chen, Jinfei |
author_sort | Zhao, Tingting |
collection | PubMed |
description | Sorafenib has been approved for the treatment of certain cancers in clinic. However, the effects of sorafenib on gastric adenocarcinoma (GAC) were still limited. This study aimed to evaluate both in vitro and in vivo efficacy of sorafenib in combination with pterostilbene (PTE) on the treatment of GAC. Here, the morphological changes and cell viability were recorded in both N87 and MKN45 cells. The cell cycle profile and apoptosis were assessed by flow cytometry. Subcutaneous tumour xenografts were constructed in nude mice, and IHC staining of the dissected tumour tissues was conducted. Our results showed that PTE enhanced sorafenib's inhibitory effects on cell viability. The obvious down‐regulation of cyclin D1, Cdk‐2, Cdk‐4, Cdk‐6 and p62 and the up‐regulation of LC3II, caspase‐9, caspase‐3 and PARP cleavages were observed for the combination treatment with PTE and sorafenib than monotherapy. The combination treatment resulted in a higher level of cell cycle arrest at G1 phase and apoptosis than either drug. Besides, drug combination significantly enhanced the inhibition of tumour growth than sorafenib or PET alone in nude mice. The percentage of Ki‐67‐ and PCNA‐positive cells was distinctly reduced, and the apoptotic cells was obviously increased when compared with single drug therapy. Altogether, PET obviously enhanced sorafenib's antitumour effects against GAC through inhibiting cell proliferation, inducing autophagy and promoting apoptosis. The combination therapy with PET and sorafenib may serve as a novel therapeutic strategy for treating GAC and deserve further clinical trials. |
format | Online Article Text |
id | pubmed-7686996 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76869962020-12-03 Pterostilbene enhances sorafenib’s anticancer effects on gastric adenocarcinoma Zhao, Tingting Wang, Chun Huo, Xinying He, Ming‐Liang Chen, Jinfei J Cell Mol Med Original Articles Sorafenib has been approved for the treatment of certain cancers in clinic. However, the effects of sorafenib on gastric adenocarcinoma (GAC) were still limited. This study aimed to evaluate both in vitro and in vivo efficacy of sorafenib in combination with pterostilbene (PTE) on the treatment of GAC. Here, the morphological changes and cell viability were recorded in both N87 and MKN45 cells. The cell cycle profile and apoptosis were assessed by flow cytometry. Subcutaneous tumour xenografts were constructed in nude mice, and IHC staining of the dissected tumour tissues was conducted. Our results showed that PTE enhanced sorafenib's inhibitory effects on cell viability. The obvious down‐regulation of cyclin D1, Cdk‐2, Cdk‐4, Cdk‐6 and p62 and the up‐regulation of LC3II, caspase‐9, caspase‐3 and PARP cleavages were observed for the combination treatment with PTE and sorafenib than monotherapy. The combination treatment resulted in a higher level of cell cycle arrest at G1 phase and apoptosis than either drug. Besides, drug combination significantly enhanced the inhibition of tumour growth than sorafenib or PET alone in nude mice. The percentage of Ki‐67‐ and PCNA‐positive cells was distinctly reduced, and the apoptotic cells was obviously increased when compared with single drug therapy. Altogether, PET obviously enhanced sorafenib's antitumour effects against GAC through inhibiting cell proliferation, inducing autophagy and promoting apoptosis. The combination therapy with PET and sorafenib may serve as a novel therapeutic strategy for treating GAC and deserve further clinical trials. John Wiley and Sons Inc. 2020-10-13 2020-11 /pmc/articles/PMC7686996/ /pubmed/33047871 http://dx.doi.org/10.1111/jcmm.15795 Text en © 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Zhao, Tingting Wang, Chun Huo, Xinying He, Ming‐Liang Chen, Jinfei Pterostilbene enhances sorafenib’s anticancer effects on gastric adenocarcinoma |
title | Pterostilbene enhances sorafenib’s anticancer effects on gastric adenocarcinoma |
title_full | Pterostilbene enhances sorafenib’s anticancer effects on gastric adenocarcinoma |
title_fullStr | Pterostilbene enhances sorafenib’s anticancer effects on gastric adenocarcinoma |
title_full_unstemmed | Pterostilbene enhances sorafenib’s anticancer effects on gastric adenocarcinoma |
title_short | Pterostilbene enhances sorafenib’s anticancer effects on gastric adenocarcinoma |
title_sort | pterostilbene enhances sorafenib’s anticancer effects on gastric adenocarcinoma |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686996/ https://www.ncbi.nlm.nih.gov/pubmed/33047871 http://dx.doi.org/10.1111/jcmm.15795 |
work_keys_str_mv | AT zhaotingting pterostilbeneenhancessorafenibsanticancereffectsongastricadenocarcinoma AT wangchun pterostilbeneenhancessorafenibsanticancereffectsongastricadenocarcinoma AT huoxinying pterostilbeneenhancessorafenibsanticancereffectsongastricadenocarcinoma AT hemingliang pterostilbeneenhancessorafenibsanticancereffectsongastricadenocarcinoma AT chenjinfei pterostilbeneenhancessorafenibsanticancereffectsongastricadenocarcinoma |